Afamelanotide and NB-UVB Light

Phase 3Small molecule

CClinuvel, Inc.

Afamelanotide and NB-UVB Light is one of 30 small molecule programs targeting Vitiligo. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

VitiligoActive, not recruiting

VitiligoPhase 3

Active, not recruiting

Competition

Competitive Landscape

36 competitors in Vitiligo

#DrugCompanyPhaseTrials

Jakafi

Incyte

Approved

8 2

Trexall

Jazz Pharmaceuticals

Approved

2 3

Cosentyx

Novartis

Approved

1 4

Xalatan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 5

Decadron

AAspen Global Incorporated

Approved

2 6

Asmanex

PPerrigo Company

Approved

1 7

Adrucil

EElorac, Inc.

Approved

—8

Elidel

BBausch Health Americas, Inc.

Approved

—9

Rapamune

PPrism Pharmaceuticals

Rinvoq

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vitiligo1 trial

A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

Active, not recruiting·CClinuvel, Inc.·Phase 3·NCT06109649·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Afamelanotide and NB-UVB Light. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Afamelanotide and NB-UVB Light compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Afamelanotide and NB-UVB Light. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Clinuvel, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CClinuvel, Inc.

Afamelanotide and NB-UVB Light

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vitiligo1 trial

References

Drug Info

Quick Facts

Related News